SCHEMBL30925456

SCHEMBL30925456

Cc1nccnc1S(=O)(=O)Nc1ccc(N2CCOCC2)c2cccnc12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC40A1 Q9NP59 7/20 0.72
▸ TDP1 Q9NUW8 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ ALDH1A1 P00352 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ GAA P10253 2/20 0.43
▸ CKS1B P61024 3/20 0.43
▸ SKP2 Q13309 3/20 0.43
▸ PKM P14618 1/20 0.43
▸ HTT P42858 4/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ CREBBP Q92793 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27214322 1.00 SLC40A1 (0.72) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL17506516 0.85 SLC40A1 (0.82) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL11973035 0.84 SLC40A1 (1.00) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL30925584 0.81 SLC40A1 (0.72) SLC40A1TDP1MEN1KMT2AGAA
SCHEMBL11973763 0.80 SLC40A1 (0.74) SLC40A1TDP1MEN1KMT2APOLB
SCHEMBL26964435 0.80 SLC40A1 (0.76) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL30553404 0.80 SLC40A1 (0.76) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL11997100 0.79 SLC40A1 (0.71) SLC40A1TDP1MEN1KMT2AALDH1A1
SCHEMBL30925429 0.79 SLC40A1 (0.68) SLC40A1TDP1MEN1KMT2AGAA
SCHEMBL27214269 0.79 SLC40A1 (0.68) SLC40A1TDP1MEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ZOETIS LLC 2024-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240148744-A1 SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES ARSA, MRPS2, SULT2A1 SLC40A1 3357/4885TDP1 4247/4885MEN1 2604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback